Haemophilia B Clinical Trial
Official title:
An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients.
NCT number | NCT02231944 |
Other study ID # | R9VFSE |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | September 2, 2014 |
Last updated | February 20, 2018 |
Start date | July 1997 |
Verified date | February 2018 |
Source | Bio Products Laboratory |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the first and second recovery assessments on Replenine®-VF and to evaluate
recovery of different batches if patients changed batches during the study.
To evaluate Replenine®-VF in terms of long-term clinical efficacy, tolerance and safety
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | October 2003 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: - Previously treated patients - At least 12 years of age - Severe Haemophilia B and without inhibitor to factor IX Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
Poland | Klinika Hematologii Instytutu Medycyny Wewnetrznej | Lodz | |
Poland | Klinika Hematologii AM Lublin, ul.Jaczewskiego 8 | Lublin | |
United Kingdom | Addenbrooke's Hospital, Hills Road | Cambridge | |
United Kingdom | University Hospital of Wales, Heath Park | Cardiff | |
United Kingdom | The Royal London Hospital | London | |
United Kingdom | Manchester Royal Infirmary, Oxford Road | Manchester | |
United Kingdom | Norwich and Norfolk Hospital | Norwich |
Lead Sponsor | Collaborator |
---|---|
Bio Products Laboratory |
Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recovery calculated from the first infusion of Replenine®-VF compared with that calculated 12 weeks later. | Safety assessments included: assessment of tolerance at injection site assessment of Factor IX inhibitor development assessment of frequency and type of adverse event routine biochemistry and haematology at the start and end of Stage 1 and at the end of the study (Stage 2, if applicable) screening for markers of viral infection at the start and end of each stage of the study (and if patients changed batches). |
Baseline and 3 months post-baseline. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03660774 -
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
|
||
Completed |
NCT02568202 -
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
|
N/A | |
Completed |
NCT01949792 -
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
|
Phase 1 | |
Completed |
NCT01562587 -
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
|
Phase 1 | |
Completed |
NCT03655340 -
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
|
||
Completed |
NCT03276130 -
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
|
||
Completed |
NCT01228669 -
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
|
Phase 1 | |
Completed |
NCT01988532 -
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
|
N/A | |
Completed |
NCT01234545 -
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
|
N/A | |
Enrolling by invitation |
NCT03690336 -
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
|
||
Completed |
NCT02241694 -
To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives
|
N/A | |
Completed |
NCT01220141 -
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
|
N/A | |
Completed |
NCT01562457 -
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
|
Phase 1 | |
Completed |
NCT03055611 -
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
|
||
Active, not recruiting |
NCT05365217 -
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
|
Phase 3 | |
Completed |
NCT01467427 -
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
|
Phase 3 | |
Completed |
NCT03075670 -
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
|
Phase 1 | |
Completed |
NCT02300519 -
Thrombin Generation Numerical Models Validation in Haemophilic Case
|
N/A | |
Withdrawn |
NCT02084810 -
Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01959555 -
Project to Update the Study of Congenital Haemophilia in Spain
|
N/A |